JAMA Neurology Publishes Data from Zogenix Phase 3 Trial Evaluating Fintepla in Patients with Dravet Syndrome Taking Stiripentol-Containing Antiepileptic Drug Regimens

JAMA Neurology Publishes Data from Zogenix Phase 3 Trial Evaluating Fintepla in Patients with Dravet Syndrome Taking Stiripentol-Containing Antiepileptic Drug Regimens

Zogenix announced JAMA Neurology, has published the results of Zogenix’s Phase 3 Study 1504 which evaluated Fintepla (ZX008, fenfluramine oral solution) in Dravet syndrome patients whose antiepileptic drug treatment regimens included stiripentol but who were still...

Pin It on Pinterest